JP2008515778A - 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療 - Google Patents

眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療 Download PDF

Info

Publication number
JP2008515778A
JP2008515778A JP2007528024A JP2007528024A JP2008515778A JP 2008515778 A JP2008515778 A JP 2008515778A JP 2007528024 A JP2007528024 A JP 2007528024A JP 2007528024 A JP2007528024 A JP 2007528024A JP 2008515778 A JP2008515778 A JP 2008515778A
Authority
JP
Japan
Prior art keywords
agent
group
effective amount
mammal
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007528024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515778A5 (https=
Inventor
ケネス ウィダー，
ジェイ リヒター，
Original Assignee
シリオン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シリオン セラピューティクス， インコーポレイテッド filed Critical シリオン セラピューティクス， インコーポレイテッド
Publication of JP2008515778A publication Critical patent/JP2008515778A/ja
Publication of JP2008515778A5 publication Critical patent/JP2008515778A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007528024A 2004-08-18 2005-08-17 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療 Pending JP2008515778A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60267504P 2004-08-18 2004-08-18
PCT/US2005/029455 WO2006033734A2 (en) 2004-08-18 2005-08-17 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders

Publications (2)

Publication Number Publication Date
JP2008515778A true JP2008515778A (ja) 2008-05-15
JP2008515778A5 JP2008515778A5 (https=) 2008-09-11

Family

ID=35351948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528024A Pending JP2008515778A (ja) 2004-08-18 2005-08-17 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療

Country Status (6)

Country Link
US (1) US20080254140A1 (https=)
EP (1) EP1778207A2 (https=)
JP (1) JP2008515778A (https=)
AU (1) AU2005287343A1 (https=)
CA (1) CA2575265A1 (https=)
WO (1) WO2006033734A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511789A (ja) * 2008-02-11 2011-04-14 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
JP2015528825A (ja) * 2012-08-17 2015-10-01 ファーマキング カンパニー リミテッドＰｈａｒｍａｋｉｎｇ Ｃｏ．， Ｌｔｄ． Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ587006A (en) 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
JP2008519054A (ja) 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
CA2584845C (en) * 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
WO2008013984A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
WO2009035673A1 (en) * 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
IN2012DN00352A (https=) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CN102612375B (zh) 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
WO2011059474A1 (en) * 2009-10-30 2011-05-19 Nestec S.A. Methods for maintaining eye health and ameliorating opthalmic maladies in canines
CN107308143A (zh) 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
GB201014340D0 (en) * 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
JP5951625B2 (ja) 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
WO2012135432A2 (en) * 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
JP6576636B2 (ja) 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
WO2013166040A1 (en) * 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York S-fta and s-fta analogues capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular degeneration, stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES3012058T3 (en) * 2014-02-13 2025-04-08 Katairo Gmbh Compounds for the treatment of lipofuscin related diseases
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533169A (ja) * 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
WO2004052283A2 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
WO2004052227A2 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
JP2008504257A (ja) * 2004-06-23 2008-02-14 シリオン セラピューティクス， インコーポレイテッド レチナール誘導体で眼科的な状態を処置するための方法および組成物
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506917B1 (en) * 1991-12-18 2003-01-14 The Salk Institute For Biological Studies Compounds and compositions useful for modulation of processes mediated by RXR
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
CO5150167A1 (es) * 1998-12-04 2002-04-29 Johnson & Johnson Consumer Composiciones para el cuidado de la piel, que contienen sales de cinc y retinoides
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
US20080176952A1 (en) * 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533169A (ja) * 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
WO2004052283A2 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
WO2004052227A2 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
JP2008504257A (ja) * 2004-06-23 2008-02-14 シリオン セラピューティクス， インコーポレイテッド レチナール誘導体で眼科的な状態を処置するための方法および組成物
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511789A (ja) * 2008-02-11 2011-04-14 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
JP2015528825A (ja) * 2012-08-17 2015-10-01 ファーマキング カンパニー リミテッドＰｈａｒｍａｋｉｎｇ Ｃｏ．， Ｌｔｄ． Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤

Also Published As

Publication number Publication date
WO2006033734A2 (en) 2006-03-30
CA2575265A1 (en) 2006-03-30
US20080254140A1 (en) 2008-10-16
EP1778207A2 (en) 2007-05-02
WO2006033734A3 (en) 2006-08-03
AU2005287343A2 (en) 2006-03-30
AU2005287343A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
JP2008515778A (ja) 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
JP4855396B2 (ja) レチナール誘導体で眼科的な状態を処置するための方法および組成物
US20120288568A1 (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation
JP2010540541A (ja) レチノール関連疾患を治療するための方法及び化合物
EP2427052B1 (en) Compositions for use in the treatment of glaucoma or ocular hypertension
CN1976692B (zh) 用视黄基衍生物治疗眼部疾病的方法和组合物
HK1107671B (en) Methods and compositions for treating ophthalmic conditions with retinyl derivatives
HK1122744B (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120510